Effects of a Th1- Versus a Th2-biased Immune Response in Protection Against Helicobacter Pylori Challenge in Mice

Overview

Journal Microb Pathog

Specialties Infectious Diseases
Microbiology

Date 2007 Aug 9

PMID 17683897

Citations 22

Authors

Jennifer M Taylor

Melanie E Ziman

Don R Canfield

Michael Vajdy

Jay V Solnick

Affiliations

Soon will be listed here.

Abstract

The roles that T helper type 1 (Th1) and T helper type 2 (Th2) Helicobacter pylori-specific immune responses play in protection from H. pylori challenge are poorly understood. It is expected that Th2 immune responses are required for protection against extracellular bacteria, such as H. pylori. However, recent studies have suggested that Th1 immunity is required for protection. The mechanisms by which this might occur are unknown. Our goal in this study was to more clearly define the effects of a Th1- versus a Th2-promoting H. pylori vaccine on immunity and protection. Therefore, we tested a Th1 vaccine consisting of an H. pylori sonicate and CpG oligonucleotides (CpG) and a Th2 vaccine consisting of a lipopolysaccharide (LPS)-depleted H. pylori sonicate combined with cholera toxin (CT). We demonstrate that although the Th2-promoting vaccine induced stronger systemic and local immune responses, only the Th1-promoting vaccine was protective.

Citing Articles

The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice.

Zhang W, Pfeifle A, Lansdell C, Frahm G, Cecillon J, Tamming L Vaccines (Basel). 2023; 11(10).

PMID: 37896985 PMC: 10610642. DOI: 10.3390/vaccines11101580.

A Genetic and Immunohistochemical Analysis of Helicobacter pylori Phenotypes and p27 Expression in Adenocarcinoma Patients in Jordan.

Al-Sheboul S, Mohammad A, Shboul Y, Brown B, Matalka I J Epidemiol Glob Health. 2023; 13(2):212-225.

PMID: 37071369 PMC: 10272050. DOI: 10.1007/s44197-023-00099-z.

Disruption of sncRNA Improves the Protective Efficacy of Outer Membrane Vesicles against Helicobacter pylori Infection in a Mouse Model.

Li B, Xu Y, Xu T, Guo Z, Xu Q, Li Y Infect Immun. 2022; 90(8):e0026722.

PMID: 35861532 PMC: 9387243. DOI: 10.1128/iai.00267-22.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J JCI Insight. 2022; 7(7).

PMID: 35192543 PMC: 9057612. DOI: 10.1172/jci.insight.157031.

Outer Membrane Vesicles of 7.13 as Adjuvants Promote Protective Efficacy Against Infection.

Song Z, Li B, Zhang Y, Li R, Ruan H, Wu J Front Microbiol. 2020; 11:1340.

PMID: 32733396 PMC: 7358646. DOI: 10.3389/fmicb.2020.01340.

References

Ikewaki J, Nishizono A, Goto T, Fujioka T, Mifune K . Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol. 2000; 44(1):29-39. DOI: 10.1111/j.1348-0421.2000.tb01243.x. View

Lundgren A, Trollmo C, Edebo A, Svennerholm A, Lundin B . Helicobacter pylori-specific CD4+ T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun. 2005; 73(9):5612-9. PMC: 1231054. DOI: 10.1128/IAI.73.9.5612-5619.2005. View

Kamradt A, Greiner M, Ghiara P, Kaufmann S . Helicobacter pylori infection in wild-type and cytokine-deficient C57BL/6 and BALB/c mouse mutants. Microbes Infect. 2000; 2(6):593-7. DOI: 10.1016/s1286-4579(00)00367-1. View

McCluskie M, Davis H . Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000; 19(4-5):413-22. DOI: 10.1016/s0264-410x(00)00208-5. View

Del Giudice G, Covacci A, Telford J, Montecucco C, Rappuoli R . The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 2001; 19:523-63. DOI: 10.1146/annurev.immunol.19.1.523. View

Cao W, Chen Y, Alkan S, Subramaniam A, Long F, Liu H . Human T helper (Th) cell lineage commitment is not directly linked to the secretion of IFN-gamma or IL-4: characterization of Th cells isolated by FACS based on IFN-gamma and IL-4 secretion. Eur J Immunol. 2005; 35(9):2709-17. DOI: 10.1002/eji.200425957. View

Jeremy A, Du Y, Dixon M, Robinson P, Crabtree J . Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination. Microbes Infect. 2005; 8(2):340-6. DOI: 10.1016/j.micinf.2005.06.025. View

Taylor J, Ziman M, Huff J, Moroski N, Vajdy M, Solnick J . Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine. 2006; 24(23):4987-94. DOI: 10.1016/j.vaccine.2006.03.043. View

Kusters J, Van Vliet A, Kuipers E . Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006; 19(3):449-90. PMC: 1539101. DOI: 10.1128/CMR.00054-05. View

10.

Aspholm M, Olfat F, Norden J, Sonden B, Lundberg C, Sjostrom R . SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog. 2006; 2(10):e110. PMC: 1626103. DOI: 10.1371/journal.ppat.0020110. View

11.

Necchi V, Candusso M, Tava F, Luinetti O, Ventura U, Fiocca R . Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology. 2007; 132(3):1009-23. DOI: 10.1053/j.gastro.2007.01.049. View

12.

Dubois A, Boren T . Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol. 2007; 9(5):1108-16. PMC: 1913845. DOI: 10.1111/j.1462-5822.2007.00921.x. View

13.

Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F . The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med. 2000; 191(9):1467-76. PMC: 2213429. DOI: 10.1084/jem.191.9.1467. View

14.

Kotloff K, Sztein M, Wasserman S, Losonsky G, DiLorenzo S, Walker R . Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001; 69(6):3581-90. PMC: 98341. DOI: 10.1128/IAI.69.6.3581-3590.2001. View

15.

Amieva M, Salama N, Tompkins L, Falkow S . Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol. 2002; 4(10):677-90. DOI: 10.1046/j.1462-5822.2002.00222.x. View

16.

Suerbaum S, Michetti P . Helicobacter pylori infection. N Engl J Med. 2002; 347(15):1175-86. DOI: 10.1056/NEJMra020542. View

17.

Maeda K, Yamashiro T, Minoura T, Fujioka T, Nasu M, Nishizono A . Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol Immunol. 2002; 46(9):613-20. DOI: 10.1111/j.1348-0421.2002.tb02742.x. View

18.

Akhiani A, Pappo J, Kabok Z, Schon K, Gao W, Franzen L . Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol. 2002; 169(12):6977-84. DOI: 10.4049/jimmunol.169.12.6977. View

19.

Kursar M, Bonhagen K, Fensterle J, Kohler A, Hurwitz R, Kamradt T . Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med. 2002; 196(12):1585-92. PMC: 2196063. DOI: 10.1084/jem.20011347. View

20.

Garhart C, Heinzel F, Czinn S, Nedrud J . Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun. 2003; 71(2):910-21. PMC: 145373. DOI: 10.1128/IAI.71.2.910-921.2003. View